Literature DB >> 33584999

An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents.

Amir Sadeghi1, Mohammad Reza Zali1, Hamid Mohaghegh Shalmani1, Pardis Ketabi Moghadam1, Mohsen Rajabnia Chenari1, Mohammad Ali Karimi1, Sina Salari2, Hamid Asadzadeh-Aghdaei3.   

Abstract

Gastrointestinal bleeding is an overwhelming complication of patients taking antithrombotic agents. These drugs pose a challenge to physicians in the management of bleeding to establish hemostasis without putting these patients at a higher risk for thromboembolism. This study aims to propose an algorithmic approach to four major groups of patients receiving antithrombotic agents (single antiplatelet agents, dual antiplatelet agents, anticoagulants and direct oral anticoagulants) to decide when and how these drugs should be held or restarted to offset between the risk of re-bleeding and thromboembolism. Four case-based algorithms are proposed in this article based on some relevant articles. Having designed four case-based algorithms, we are hoping to guide physicians who face a dilemma on the management of patients receiving antithrombotics when gastrointestinal bleeding occurs. Patients using antithrombotics referred for gastrointestinal bleeding were stratified into four groups based on the medication which is used as an antithrombotic agent and four algorithms were designed which are presented here. We have made an attempt to have a stepwise approach to four cases relevant to the study and have an evaluation on the management of their antithrombotic agents during an episode of gastrointestinal bleeding. It is widely accepted that antithrombotic agents should be restarted as soon as possible after the establishment of hemostasis in a patient taking antithrombotics referring for gastrointestinal bleeding. The time for resuming these drugs is different based on the severity of bleeding, the probability of thromboembolic events, and the nature of the antithrombotic medication which is used by the patient. ©2020 RIGLD, Research Institute for Gastroenterology and Liver Diseases.

Entities:  

Keywords:  Algorithms; Antithrombotic agents; Gastrointestinal bleeding; Thromboembolic events

Year:  2020        PMID: 33584999      PMCID: PMC7881411     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol Bed Bench        ISSN: 2008-2258


  44 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  Seroprevalence of hepatitis B in Nahavand, Islamic Republic of Iran.

Authors:  A H M Alizadeh; M Ranjbar; S Ansari; A MirArab; S M Alavian; K Mohammad; P Adibi; Gh H Sadri; F Keramat; A Ardalan; M Arabi; S Gharekhani; A Ataei; Gh R Amraei; M Hosseinzadeh; S Hatami; M Zali
Journal:  East Mediterr Health J       Date:  2006-09       Impact factor: 1.628

3.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

4.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

5.  Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.

Authors:  Dmytro Khadzhynov; Frank Wagner; Stephan Formella; Erol Wiegert; Viktoria Moschetti; Torsten Slowinski; Hans-H Neumayer; Karl-Heinz Liesenfeld; Thorsten Lehr; Sebastian Härtter; Jeffrey Friedman; Harm Peters; Andreas Clemens
Journal:  Thromb Haemost       Date:  2013-02-07       Impact factor: 5.249

6.  Determination of Helicobacter pylori virulence by analysis of the cag pathogenicity island isolated from Iranian patients.

Authors:  K Baghaei; L Shokrzadeh; F Jafari; H Dabiri; Y Yamaoka; M Bolfion; H Zojaji; M M Aslani; M R Zali
Journal:  Dig Liver Dis       Date:  2009-03-03       Impact factor: 4.088

Review 7.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.

Authors:  K Martin; J Beyer-Westendorf; B L Davidson; M V Huisman; P M Sandset; S Moll
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

8.  Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.

Authors:  Sigrun Halvorsen; Robert F Storey; Bianca Rocca; Dirk Sibbing; Jurrien Ten Berg; Erik Lerkevang Grove; Thomas W Weiss; Jean-Philippe Collet; Felicita Andreotti; Dietrich C Gulba; Gregory Y H Lip; Steen Husted; Gemma Vilahur; Joao Morais; Freek W A Verheugt; Angel Lanas; Rustam Al-Shahi Salman; Philippe Gabriel Steg; Kurt Huber
Journal:  Eur Heart J       Date:  2017-05-14       Impact factor: 29.983

9.  Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.

Authors:  Andrew M Veitch; Geoffroy Vanbiervliet; Anthony H Gershlick; Christian Boustiere; Trevor P Baglin; Lesley-Ann Smith; Franco Radaelli; Evelyn Knight; Ian M Gralnek; Cesare Hassan; Jean-Marc Dumonceau
Journal:  Gut       Date:  2016-03       Impact factor: 23.059

10.  Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding.

Authors:  Naoyoshi Nagata; Toshiyuki Sakurai; Shiori Moriyasu; Takuro Shimbo; Hidetaka Okubo; Kazuhiro Watanabe; Chizu Yokoi; Mikio Yanase; Junichi Akiyama; Naomi Uemura
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.